Breaking News Instant updates and real-time market news.

BTAI

BioXcel Therapeutics

$10.67

(0.00%)

, NKTR

Nektar

$31.33

-0.82 (-2.55%)

08:07
06/03/19
06/03
08:07
06/03/19
08:07

BioXcel Therapeutics announces FDA clearance of IND for BXCL701 therapy

BioXcel Therapeutics (BTAI) announced an update of its immuno-oncology program for BXCL701, an orally-available systemic innate-immune activator with dual mechanisms of action. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology. BTI reported that its Investigational New Drug application has received clearance from the U.S. Food and Drug Administration to start a clinical trial to evaluate the triple combination of BXCL701, bempegaldesleukin and avelumab for the treatment of pancreatic cancer as a second line therapy. BTI is collaborating with Nektar Therapeutics (NKTR), Merck KGaA (MKGAY) and Pfizer (PFE) to conduct this trial. Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center, will serve as the Principal Investigator. In addition, BTI announcedthe acceptance of the company's clinical trial authorization by the UK's MHRA of a trial evaluating the combination of BXCL701 and pembrolizumab in tNEPC. Under the supervision of the European Principal Investigator, Professor Johann de Bono, M.D., Ph.D. of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, BTI plans to open its Phase 1b/2 study of BXCL701 and Keytruda in tNEPC, a hormone-refractory form of prostate cancer, in the UK. BTI currently believes that no viable treatment option exists for this type of cancer. The Company has opened multiple sites in the US, and data from the open-label trial is expected to support the ongoing global clinical development of BXCL701.

BTAI

BioXcel Therapeutics

$10.67

(0.00%)

NKTR

Nektar

$31.33

-0.82 (-2.55%)

MKGAY

Merck KGaA

$0.00

(0.00%)

PFE

Pfizer

$41.53

-0.37 (-0.88%)

  • 04

    Jun

  • 12

    Jun

BTAI BioXcel Therapeutics
$10.67

(0.00%)

12/05/18
HCWC
12/05/18
NO CHANGE
Target $25
HCWC
Buy
BioXcel Therapeutics data establish proof-of-concept, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju reiterates a Buy rating on BioXcel Therapeutics with a $25 price target after the company reported that its Phase 1b dose-ranging study of IV form of BXCL501 met the primary endpoint, with 90% of the 10 schizophrenic patients enrolled reaching a Richmond Agitation-Sedation Scale score of -1 without any significant adverse effects being observed. These data provide confirmation that BXCL501 effectively produces arousable sedation in both schizophrenic and bipolar patients, Selvaraju tells investors in a research note. The analyst anticipates that the Phase 1b data in Alzheimer's disease patients, slated for release in the coming weeks, is likely to similarly provide proof-of-concept referential evidence of sedation, albeit perhaps with a different pharmacokinetic profile.
NKTR Nektar
$31.33

-0.82 (-2.55%)

06/02/19
PIPR
06/02/19
NO CHANGE
Target $100
PIPR
Overweight
Nektar should be up on data from Bempeg CRR in melanoma, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $100 price target on Nektar, and believes shares should be up significantly on Monday following updated data from the bempegaldesleukin + nivo PIVOT-02 melanoma cohort. The increase in complete response rate from 24% to 34% at just beyond 12 months is more than the analyst and investors were anticipating and "the waterfall plot is like nothing [he has] ever seen in solid tumors." Ultimately, Van Buren believes the high quality of responses and the ability to maintain patients on therapy is contributing to robust durability, which increases his confidence in the ultimate outcome of the Phase III trial which will have a final mPFS evaluation around Q3 of 2020.
05/24/19
MZHO
05/24/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho reiterates $81 price target on Nektar after management meetings
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with an $81 price target after hosting investor meetings with management. Investors remain focused on NKTR-214, says the analyst, who remains encouraged by the available data to date from Pivot across several indications. Yang admits, however, that Phase III readouts will be needed to confirm her view on NKTR-214. In the meantime, the upcoming data updates at ASCO for melanoma and ESMO for non-small-cell lung carcinoma could be catalysts for Nektar shares, Yang tells investors in a research note.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $100
PIPR
Overweight
Nektar update at ASCO likely to be positive, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren keeps an Overweight rating on Nektar Therapeutics with a $100 price target followign the company's Q1 results. The analyst looks forward to the melanoma Pivot-02 cohort update at the American Society of Clinical Oncology meeting. He believes the update is likely to be positive.
03/15/19
LEER
03/15/19
INITIATION
Target $38
LEER
Market Perform
Nektar initiated with a Market Perform at SVB Leerink
SVB Leerink initiated Nektar with a Market Perform and $38 price target.
MKGAY Merck KGaA
$0.00

(0.00%)

04/16/19
04/16/19
DOWNGRADE
Target $53

Hold
Versum Materials downgraded to Hold from Buy at Loop Capital
As previously reported, Loop Capital analyst Chris Kapsch downgraded Versum Materials (VSM) to Hold and lowered his price target to $53 from $56, saying the bidding process for the company has "run its course" after its board agreed to Merck KGaA's (MKGAY) "sweetened" deal over that of Entegris' (ENTG) merger of equals proposal. The analyst says the stock has limited upside from its current levels and expects the deal to close in the second half of 2019.
04/08/19
STFL
04/08/19
DOWNGRADE
Target $53
STFL
Hold
Versum Materials downgraded to Hold from Buy at Stifel
Stifel analyst Patrick Ho downgraded Versum Materials (VSM) to Hold from Buy after the company received a revised all-cash offer of $53 per share offer from Merck KGaA (MKGAY) and Entegris (ENTG) announced in a press release that it would not counter this bid. With Entegris turning down a potential counter and walking away, Ho said he does not believe there will be any additional counter, hostile, or unsolicited bidding. He raised his price target for Versum shares to $53 from $46.
04/03/19
04/03/19
UPGRADE
Target $56

Buy
Versum Materials upgraded to Buy at Loop Capital on deal prospects
As previously reported, Loop Capital analyst Chris Kapsch upgraded Versum Materials (VSM) to Buy from Hold and raised his price target for the shares to $56 from $53. The analyst say he "really likes" the potential combination with Entegris (ENTG) if it is successful in acquiring the company, as the merged entity would "create a premier mid-cap specialty materials company". Kapsch also speculates that Merck KGaA (MKGAY) is likely to increase its offer to acquire Versum even as the latter's board has "unequivocally spurned" the all-cash $48/share takeout bid and believes the revised proposal could come before the April 26th shareholder vote on the proposed merger of equals with Entegris.
03/15/19
UBSW
03/15/19
DOWNGRADE
UBSW
Neutral
Merck KGaA downgraded to Neutral from Buy at UBS
UBS analyst Michael Leuchten downgraded Merck KGaA to Neutral from Buy saying the stock's valuation is now close to his sum-of-the parts analysis. The analyst believes near-term catalysts are now priced into the shares. He lowered his price target for Merck KGaA to EUR 108 from EUR 115.
PFE Pfizer
$41.53

-0.37 (-0.88%)

05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/29/19
CANT
05/29/19
NO CHANGE
Target $53
CANT
Overweight
Pfizer sales potential Vyndaqel/Vyndamax underappreciated, says Cantor
Cantor Fitzgerald analyst Louise Chen says her "quick poll" of cardiologists supports the view that the peak sales potential of Pfizer's Vyndaqel/Vyndamax is underappreciated. The sales could be "meaningfully higher" than the 2024 consensus forecasts of $1.5B given a treatment cost of $225,000 per patient per year and a potential treatment population of 1M-plus in the U.S., Chen tells investors in a research note. She thinks the growing usage of scintigraphy for diagnosing transthyretin amyloid cardiomyopathy will increase the number of patients that are identified and eligible for treatment. The analyst reiterates an Overweight rating on Pfizer with a $53 price target.
05/28/19
GSCO
05/28/19
INITIATION
Target $49
GSCO
Conviction Buy
Pfizer initiated with a Conviction Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Pfizer with a Buy rating and added the shares to his firm's Americas Conviction List. He has a $49 price target for the shares. Flynn expects Pfizer's growth to inflect in 2021 with revenue of $57.4B, ahead of the $56B consensus estimate. He also projects the company's operating margins will expand from 38.1% in 2019 to 40.6% in 2022 as revenue growth outpaces expenses.
05/28/19
PIPR
05/28/19
NO CHANGE
PIPR
Piper more bullish on GlycoMimetics, Global Blood into upcoming catalysts
After surveying 25 sickle cell disease experts, Piper Jaffray analyst Danielle Brill is "incrementally more bullish" on both GlycoMimetics (GLYC) and Global Blood Therapeutics (GBT) into their upcoming catalysts. GlycoMimetics and partner Pfizer (PFE) have pivotal Phase 3 results with rivipansel, their pan-selectin inhibitor, reading out in July, Brill tells investors in a research note. And Global Blood Therapeutics is expected to complete its new drug application submission for voxelotor via the accelerated approval pathway and present full Phase 3 Hope trial data in June, adds the analyst. Following expert feedback, Brill remains confident for a successful Phase 3 outcome with rivipansel. She believes positive data will drive GlycoMimetics shares "meaningfully higher" in July. Further, the majority of the surveyed doctors believe voxelotor's hemolytic anemia benefit is clinically relevant and most expect accelerated approval based on these data, adds the analyst.

TODAY'S FREE FLY STORIES

01:50
11/19/19
11/19
01:50
11/19/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

EFC

Ellington Financial

$18.79

0.01 (0.05%)

20:29
11/18/19
11/18
20:29
11/18/19
20:29
Syndicate
Ellington Financial 4.2M share Spot Secondary priced at $18.20 »

The stock priced below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HD

Home Depot

$238.98

1.64 (0.69%)

, MDT

Medtronic

$111.25

-0.86 (-0.77%)

20:25
11/18/19
11/18
20:25
11/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HD

Home Depot

$238.98

1.64 (0.69%)

MDT

Medtronic

$111.25

-0.86 (-0.77%)

TJX

TJX

$59.54

-0.25 (-0.42%)

TDG

TransDigm

$568.32

9.81 (1.76%)

ARMK

Aramark

$43.90

0.25 (0.57%)

KSS

Kohl's

$58.39

-0.71 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 05

    Dec

  • 11

    Dec

ACY

AeroCentury

$3.31

-0.66 (-16.62%)

20:01
11/18/19
11/18
20:01
11/18/19
20:01
Hot Stocks
AeroCentury sells one Bombardier CRJ900 to Aeronautical Support International »

AeroCentury announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$6.02

-0.14 (-2.27%)

19:29
11/18/19
11/18
19:29
11/18/19
19:29
Hot Stocks
Myovant Sciences up over 11% after announcing Phase 3 Study conference call »

Shares of Myovant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$29.95

-0.04 (-0.13%)

18:47
11/18/19
11/18
18:47
11/18/19
18:47
Hot Stocks
Invitation Homes CEO sells 70K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

, LUV

Southwest

$57.77

-0.03 (-0.05%)

18:44
11/18/19
11/18
18:44
11/18/19
18:44
Periodicals
Boeing to provide Southwest board with 737 MAX update this week, Reuters says »

Boeing (BA) this week…

BA

Boeing

$369.50

-2.05 (-0.55%)

LUV

Southwest

$57.77

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GBDC

Golub Capital

$17.79

0.045 (0.25%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Upgrade
Golub Capital rating change at Keefe Bruyette »

Golub Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GM

General Motors

$36.62

-0.25 (-0.68%)

, TM

Toyota

$143.53

-0.76 (-0.53%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Periodicals
CA to halt purchase of GM, Toyota, Fiat Chrysler vehicles, Reuters reports »

The state of California…

GM

General Motors

$36.62

-0.25 (-0.68%)

TM

Toyota

$143.53

-0.76 (-0.53%)

FCAU

Fiat Chrysler

$15.63

-0.39 (-2.43%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

LEVI

Levi Strauss

$17.06

-0.115 (-0.67%)

18:31
11/18/19
11/18
18:31
11/18/19
18:31
Hot Stocks
Levi Strauss CEO: I believe in the importance of innovation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.17

0.07 (0.16%)

18:17
11/18/19
11/18
18:17
11/18/19
18:17
Periodicals
Cisco sues former employees over claims of trade secret theft, Bloomberg says »

Cisco is suing two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ABBV

AbbVie

$88.71

0.07 (0.08%)

18:09
11/18/19
11/18
18:09
11/18/19
18:09
Hot Stocks
AbbVie treatment of myelofibrosis granted FDA orphan status »

AbbVie's navitoclax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PRQR

ProQR Therapeutics

$6.27

-0.64 (-9.26%)

18:06
11/18/19
11/18
18:06
11/18/19
18:06
Hot Stocks
ProQR Therapeutics treatment of retinal dystrophy in P23H granted orphan status »

ProQR Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:04
11/18/19
11/18
18:04
11/18/19
18:04
Earnings
Bilibili sees Q4 revenue RMB1.93B-RMB1.98B »

Q4 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com sees Q4 revenue up 12%-15% in RMB terms »

Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Hot Stocks
Bilibili reports average MAUs reached 127.9M in Q3 »

Average monthly active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com reports Q3 adjusted EPS 96c, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:01
11/18/19
11/18
18:01
11/18/19
18:01
Earnings
Bilibili reports Q3 adjusted EPS (15c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

DDOG

Datadog

$40.36

-0.33 (-0.81%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:56
11/18/19
11/18
17:56
11/18/19
17:56
Hot Stocks
Datadog announces support for AWS CloudFormation Registry and CLI »

Datadog (DDOG) announced…

DDOG

Datadog

$40.36

-0.33 (-0.81%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

17:55
11/18/19
11/18
17:55
11/18/19
17:55
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

GVA

Granite Construction

$26.50

-0.6 (-2.21%)

17:54
11/18/19
11/18
17:54
11/18/19
17:54
Hot Stocks
Granite Construction awarded $14M airfield improvement project in California »

Granite announced it was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$44.46

-1.37 (-2.99%)

, MSFT

Microsoft

$150.35

0.4 (0.27%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Initiation
Zscaler, Microsoft initiated at DA Davidson »

Zscaler initiated with a…

ZS

Zscaler

$44.46

-1.37 (-2.99%)

MSFT

Microsoft

$150.35

0.4 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 16

    Dec

OKTA

Okta

$121.21

3.76 (3.20%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Upgrade
Okta rating change at DA Davidson »

Okta pullback represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

PANW

Palo Alto Networks

$248.50

1.465 (0.59%)

17:48
11/18/19
11/18
17:48
11/18/19
17:48
Initiation
Palo Alto Networks initiated at DA Davidson »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.